Biomedica osteomiR microRNA signature for osteoporosis diagnosis

Wednesday, 28 March, 2018 | Supplied by: United Bioresearch Products Pty Ltd


Osteojpg 28ps 29

osteomiRs are circulating microRNAs that serve as novel biomarkers for bone quality and musculoskeletal diseases and can improve early diagnosis of osteoporosis.

Bone densitometry (DEXA) provides the criterion for diagnosis of osteoporosis, but is not sufficiently sensitive to identify patients at immediate fracture risk. In addition, patients of type 2 diabetic osteopathy exhibit elevated fracture risk in spite of elevated bone marrow density.

The osteomiR microRNA signature is intended to assess the risk of a first fracture in female patients of postmenopausal osteoporosis and type 2 diabetes. This information enables timely interventions and can help to avoid fractures.

Biomedica has identified 11 microRNAs in human serum of osteoporotic patients, which are informative about fracture-risk in primary and secondary osteoporosis.

The osteomiR test from Biomedica is a minimally invasive and novel fracture-risk assessment tool, requiring only 200 μL of serum. It has a fast and simple workflow and includes software facilitating data analysis.

Originally published here.

Online: www.unitedbioresearch.com.au
Phone: 02 4575 0309
Related Products

  • All content Copyright © 2018 Westwick-Farrow Pty Ltd